Vanden Bempt I - Search Results

1

Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.

Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Vandenberghe P, De Wolf-Peeters C. Vanden Bempt I, et al. Histopathology. 2005 Apr;46(4):431-41. doi: 10.1111/j.1365-2559.2005.02112.x. Histopathology. 2005. PMID: 15810955

2

Comparative expressed sequence hybridization reveals differential gene expression in morphological breast cancer subtypes.

Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, De Wolf-Peeters C. Vanden Bempt I, et al. J Pathol. 2006 Mar;208(4):486-94. doi: 10.1002/path.1911. J Pathol. 2006. PMID: 16402338

3

Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling.

Vanhentenrijk V, Vanden Bempt I, Dierickx D, Verhoef G, Wlodarska I, De Wolf-Peeters C. Vanhentenrijk V, et al. Among authors: vanden bempt i. J Pathol. 2006 Oct;210(2):155-62. doi: 10.1002/path.2043. J Pathol. 2006. PMID: 16874743

4

Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age.

Van Mieghem T, Leunen K, Pochet N, De Moor B, De Smet F, Amant F, Berteloot P, Timmerman D, Vanden Bempt I, Drijkoningen R, Wildiers H, Paridaens R, Smeets A, Hendrickx W, Van Limbergen E, Christiaens MR, Vergote I, Neven P. Van Mieghem T, et al. Among authors: vanden bempt i. Breast Cancer Res Treat. 2007 Nov;106(1):127-33. doi: 10.1007/s10549-006-9474-7. Epub 2007 Jan 9. Breast Cancer Res Treat. 2007. PMID: 17211534

5

The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas.

Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, De Wolf-Peeters C, Christiaens MR, Michiels L, Bouillon R, Verstuyf A. Verlinden L, et al. Among authors: vanden bempt i. Cancer Res. 2007 Jul 15;67(14):6574-81. doi: 10.1158/0008-5472.CAN-06-3545. Cancer Res. 2007. PMID: 17638866 Free article.

6

Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.

Neven P, Van Calster B, Van den Bempt I, Van Huffel S, Van Belle V, Hendrickx W, Decock J, Wildiers H, Paridaens R, Amant F, Leunen K, Berteloot P, Timmerman D, Van Limbergen E, Weltens C, Van den Bogaert W, Smeets A, Vergote I, Christiaens MR, Drijkoningen M. Neven P, et al. Breast Cancer Res Treat. 2008 Jul;110(1):153-9. doi: 10.1007/s10549-007-9687-4. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687649

7

The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity.

Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C. Vanden Bempt I, et al. Curr Opin Oncol. 2007 Nov;19(6):552-7. doi: 10.1097/CCO.0b013e3282f0ad8e. Curr Opin Oncol. 2007. PMID: 17906451 Review.

8

Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.

Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S, Hendrickx W, Decock J, Huang HJ, Leunen K, Amant F, Berteloot P, Paridaens R, Wildiers H, Van Limbergen E, Weltens C, Timmerman D, Van Gorp T, Smeets A, Van den Bogaert W, Vergote I, Christiaens MR, Neven P. Van Calster B, et al. Among authors: vanden bempt i. Breast Cancer Res Treat. 2009 Jan;113(1):181-7. doi: 10.1007/s10549-008-9914-7. Epub 2008 Feb 9. Breast Cancer Res Treat. 2009. PMID: 18264760

9

Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.

Eelen G, Vanden Bempt I, Verlinden L, Drijkoningen M, Smeets A, Neven P, Christiaens MR, Marchal K, Bouillon R, Verstuyf A. Eelen G, et al. Among authors: vanden bempt i. Oncogene. 2008 Jul 10;27(30):4233-41. doi: 10.1038/onc.2008.51. Epub 2008 Mar 17. Oncogene. 2008. PMID: 18345034 Free article.

10

Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.

Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P. Brouckaert O, et al. Among authors: vanden bempt i. Breast Cancer Res Treat. 2009 May;115(2):349-58. doi: 10.1007/s10549-008-0110-6. Epub 2008 Jul 16. Breast Cancer Res Treat. 2009. PMID: 18629635 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results